Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Precision Medicine
for Myalgic Encephalomyelitis
Drug Discovery and ClinicaI Trials (REMEDIAL)

  • From our MAESTRO project, we have seen that the profile of circulating microRNA can distinguish between ME/CFS and Fibromyalgia (FM) patients.
  • Our diagnostic panel of 11 circulating microRNA can be used (without induction of PEM) to identify individuals suffering of ME/CFS, FM or having both conditions.
  • We have also shown that miR-150-5p is associated with POTS/OI in ME/CFS patients. We proposed that miR-150- 5p triggers POTS/OI through two distinct mechanisms:
    • Mechanism 1: Elevation of miR-150-5p expression occurs in ME/CFS patients with POTS/OI and block the translation of SLC6A2 mRNA resulting in a norepinephrine transporter (NET) deficiency.
    • Mechanism 2: Conversely, a severe reduction of miR-150- 5p expression induces a similar effect by increasing the EZH2 expression, which leads to a transcriptional repression of SLC6A2 gene, lowering NET levels. We are also exploring the role of circulating thrombospondin-1 (TSP-1) in the regulation of soluble SMPDL3B production.
    • Lastly, we have identified 8 targets as potential therapeutic options and will be exploring these further–specifically how to increase, reduce, or block these potential biomarkers of ME/CFS.

STUDY HYPOTHESIS AND DESCRIPTION

Our study will couple a deep phenotyping
characterization of ME/CFS patients to the
development of cellular and animal models
for repurposing current drugs to accelerate
the proof-of-concept of different therapeutic
interventions for ME/CFS. Indeed, precision
medicine is essential to address the clinical
complexity of ME/CFS and to identify the
best therapeutic options to cure ME/CFS.

 

OBJECTIVES

  • Deep phenotyping of ME patients through precision medicine.
  • Development of cellular and mouse models for the validation of targets.
  • Preparation and launch of pilot phase 2b clinical trials..
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669